54 synovial fluids (SFs), 46 of them derived from various inflammatory diseases (30 rheumatoid arthritis (RA) SFs, 8 undefined arthritis (UA) SFs, 8 psoriatic arthritis (PSA) SFs) and 8 SFs from degenerative joint diseases (OA) were tested for C3c split product, using the immunofixation method. There were significant differences in the C3c product between the four groups investigated. In the OA group in the mean the percentage of C3c was low in comparison to the native C3 (C3c = 2.95%). RA SFs and UA SFs showed considerably higher values (20.1% for RA and 23.2% for UA) which were statistically significant in comparison to the OA SFs. With the exception of one SF the PSA SFs exhibited a relatively low percentage of the cleavage product. Despite the one high value the average C3c content of the PSA SFs was not statistically different from the OA SFs. In contrast to this low percentage of the C3c split product the PSA SFs showed the highest C3 concentration of all groups (87.0 +/- 36.5 mg/100 ml). Immunofixation is a simple and effective tool to determine the C3c split product in SFs. It might also be helpful for establishing the differential diagnosis of PSA vs RA on the basis of the C3 level of the SF in those patients where an elevated level of C3 is present.
Download full-text PDF |
Source |
---|
IEEE Trans Ultrason Ferroelectr Freq Control
October 2024
A sparse array offers a significant reduction in the complexity of ultrasonic imaging systems by decreasing the number of active elements and associated electrical circuits needed to form a focused beam. Consequently, for 1-D arrays, it has been adopted in the development of miniaturized systems such as portable, handheld, or smartphone-based systems. Previously, we developed an analytic method that can design a pair of 1-D periodic sparse arrays (PSAs) satisfying three specific constraints, which are the array size, desired grating lobe level, and sparseness factor (SF).
View Article and Find Full Text PDFExp Biol Med (Maywood)
September 2022
Rheumatology Unit, Department of Medicine DIMED, University of Padova, 35128 Padova, Italy.
Psoriatic arthritis (PsA) is a multifaceted inflammatory disease associated with psoriasis that can affect peripheral joints, entheses, and the axial skeleton with a variable clinical course. Acute episodes of joint swelling in PsA patients can have different causes and require specific treatments. We aimed to describe the acute joint swelling in PsA patients via synovial fluid (SF) analyses, assessing in particular the presence of pathogenic crystals, to determine whether it is a flare or an acute episode of gout ("psout") during the course of the disease.
View Article and Find Full Text PDFBiomed Pharmacother
August 2022
Department of Medicine, University of Padova, Via Giustiniani 2, 35128 Padova, Italy. Electronic address:
Exp Biol Med (Maywood)
June 2022
Rheumatology Unit, Department of Medicine (DIMED), University of Padova, Padova 35128, Italy.
STING (stimulator of interferon genes) has been recognized as an important signaling molecule in the innate immune response to cytosolic nucleic acids. Although it has been proposed that STING signaling pathway may play a pathogenic role in developing autoimmune and autoinflammatory diseases, its involvement in rheumatic disease processes remains to be elucidated. Here, we evaluated STING protein levels, expression and relationship with inflammatory parameters in synovial fluid (SF) of patients with psoriatic arthritis (PsA), rheumatoid arthritis (RA), gout, calcium pyrophosphate crystal-induced arthritis (CPP-IA), osteoarthritis (OA), and OA with CPP crystals (OA + CPP).
View Article and Find Full Text PDFJ Nucl Med
October 2022
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
The aim of the study was to assess the outcome of patients with metastatic castration-resistant prostate cancer treated with Lu-prostate-specific membrane antigen (PSMA) who would have been a screen failure (SF) in the VISION trial based on PSMA PET/CT criteria. We conducted a retrospective multicenter cohort study on 301 patients with metastatic castration-resistant prostate cancer treated with Lu-PSMA. The patients were classified into eligible (VISION-PET-E) and SF (VISION-PET-SF) groups on the basis of the baseline PSMA PET/CT results.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!